TABLE 2.
Demographics, clinical characteristics, and outcomes of renal transplant recipients (n = 6,553).
| Parameters | Results |
|---|---|
| Overall Age (years, mean, SD) | 29.15 ± 10.19 |
| Adult > 18 (years, mean, SD) | 31.72 ± 8.76 |
| Paediatric ≤ 18 (years, mean, SD) | 14.66 ± 3.18 |
| Spousal (years, mean, SD) | 36.65 ± 7.75 |
| Pediatric up to 18 years (n, %) | 988 (15.1) |
| Spousal (n, %) | 601 (9.2) |
| Gender (n, %) | |
| Overall Male (n, %) | 5,154 (78.7) |
| Children Male (n, %) | 712 (72.1) |
| Spousal Male (n, %) | 510 (84.9) |
| Primary renal disease (n, %) | |
| Glomerulopathies | 1,361 (20.76) |
| Congenital/Urologic/Cystic | 340 (5.19) |
| Hypertension | 678 (10.35) |
| Diabetes | 102 (1.56) |
| Stone Disease | 568 (8.67) |
| Unknown | 3,504 (53.47) |
| Time on dialysis (months, median, IQR) | 5 (IQR: 3–10) |
| Donor Age (mean, SD) | 34.28 ± 9.67 |
| Male (n, %) | 3,690 (56.3) |
| Female (n, %) | 2,863 (43.7) |
| Donor Gender | |
| Paediatric Transplants, Females | 571 (57.8) |
| Spousal Transplants, Females | 510 (84.9) |
| HLA Match (n, %) | |
| 4–6 | 3,771 (57.5) |
| 3 | 1,988 (30.3) |
| 0–2 | 794 (12.1) |
| Panel reactive antibodies (PRA) (n, %) | |
| 0%–10% | 6,083 (92.8) |
| >10% | 470 (7.2) |
| Immunosuppression (n, %) | |
| Induction therapy (ATG/IL-2) | 1,120 (17) |
| Initial Maintenance (n, %) | |
| Cyclosporine/Aza/Steroid | 5,416 (82.65) |
| Tacrolimus/MMF/Steroid | 668 (10.19) |
| Cyclosporine/MMF/Steroid | 239 (3.6) |
| Tacrolimus/Aza/Steroid | 555 (8.4) |
| mTOR Inhibitors | 586 (8.9) |
| Acute rejection (n, %) | 1,141 (17) |
| Post-Transplant Chronic infections (n, %) | |
| Tuberculosis | 937 (14.3) |
| Recurrent UTI | 1,156 (17.6) |
| HCV | 819 (12.5) |
| CMV | 2,346 (35.8) |
| 1 and 5-year Graft Survival (n, %) | |
| Overall | 6,553, 97% and 87% |
| Paediatric | 988, 96% and 85% |
| Spousal | 601, 97% and 85% |
| 1 and 5-year Patient Survival (n, %) | |
| Overall | 6,553, 97% and 88% |
| Paediatric | 988, 97% and 90% |
| Spousal | 601, 98% and 88% |